Venus Medtech (Hangzhou) Inc. (HKG:2500)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 814.49M |
| Revenue (ttm) | 341.39M |
| Net Income (ttm) | -453.68M |
| Shares Out | 437.90M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | 180.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 621,000 |
| Average Volume | 1,093,575 |
| Open | 1.860 |
| Previous Close | 1.850 |
| Day's Range | 1.840 - 1.890 |
| 52-Week Range | 1.770 - 5.470 |
| Beta | 1.27 |
| RSI | 36.24 |
| Earnings Date | Mar 31, 2026 |
About Venus Medtech (Hangzhou)
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Ve... [Read more]
Financial Performance
In 2025, Venus Medtech (Hangzhou)'s revenue was 306.79 million, a decrease of -34.84% compared to the previous year's 470.83 million. Losses were -407.69 million, -42.92% less than in 2024.
Financial numbers in CNY Financial StatementsNews
Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations
HONG KONG, April 21, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapie...
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
HANGZHOU, China , Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapie...
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
HANGZHOU, China , June 14, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today th...
Venus Medtech VenusP-Valve transcatheter pulmonic valve replacement system granted Health Canada approval
HANGZHOU, China , Feb. 5, 2024 /PRNewswire/ -- Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today tha...
Venus Medtech's Exciting Innovations for Structural Heart to Be Showcased at London Valves 2023
The company will be presenting its growing pipeline of superb technologies for treating all four heart valves in its booth and at multiple events during the conference. HANGZHOU, China , Nov. 18, 2023...